Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.58 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.58 |
| ▸ | F11 | P03951 | 1/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890400 | 0.78 | LPL (0.73) | LPLLIPGF11ENPP2CA2 | |
| SCHEMBL13667094 | 0.78 | LPL (0.64) | LPLLIPGF11ENPP2CA2 | |
| SCHEMBL204921 | 0.76 | ENPP2 (0.73) | LPLLIPGF11ENPP2CA2 | |
| SCHEMBL97582 | 0.76 | CA1 (0.52) | CA2CA1MGLLTSHR | |
| SCHEMBL112402 | 0.76 | LPL (0.61) | LPLLIPGF11ENPP2CA2 | |
| SCHEMBL23406327 | 0.74 | LPL (0.58) | LPLLIPGF11ENPP2CA2 | |
| SCHEMBL150306 | 0.74 | LPL (1.00) | LPLLIPGF11ENPP2CA2 | |
| SCHEMBL103171 | 0.74 | F11 (0.95) | LPLLIPGF11ENPP2CA2 | |
| SCHEMBL13927971 | 0.74 | LPL (0.58) | LPLLIPGF11ENPP2CA2 | |
| SCHEMBL40256 | 0.74 | LPL (0.58) | LPLLIPGF11ENPP2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113278094-B | Cyclodextrin derivative and preparation method and application thereof | 兰州大学 | 2022-03-01 | — | — | CN | claimed |
| CN-113278094-A | Cyclodextrin derivative and preparation method and application thereof | 兰州大学 | 2021-08-20 | — | — | CN | claimed |
| US-20180312617-A1 | A CATION POLYMER CAPABLE OF REMOVING POSITIVE CHARGES THROUGH OXIDATIVE RESPONSE, A PREPARATION METHOD AND APPLICATION | ZHEJIANG UNIVERSITY (CN) | 2018-11-01 | — | — | US | claimed |
| US-12491252-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | NORTHWESTERN UNIVERSITY (US) | 2025-12-09 | — | — | US | disclosed |
| CN-119523931-B | Polypyrrole-based stimulus response type bionic drug-loaded nanoparticle and preparation method thereof | 复旦大学 | 2025-06-24 | — | — | CN | disclosed |
| CN-119523931-A | Polypyrrole-based stimulus response type bionic drug-loaded nanoparticle and preparation method thereof | 复旦大学 | 2025-02-28 | — | — | CN | disclosed |
| US-20240335546-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | NORTHWESTERN UNIVERSITY | 2024-10-10 | — | — | US | disclosed |
| US-12042543-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | NORTHWESTERN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| CN-115919748-B | Prodrug-based stimulus response type nanogel and preparation method thereof | 复旦大学 | 2024-05-17 | — | — | CN | disclosed |
| US-20230346953-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| US-20230346953-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| WO-2009151991-A1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090143580-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | MCARTHUR SILVIA GATTI | 2009-06-04 | — | — | US | disclosed |
| US-7504404-B2 | Compounds as metabotropic glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1934214-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039439-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143580-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GRM1, GRM2, GRM3 | LPL 4051/4885LIPG 4254/4885F11 2423/4885 |
| US-12042543-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | EZH2, BAZ2A, BAZ2B | LPL 2238/4885LIPG 2824/4885F11 3879/4885 |
| US-20180312617-A1 | A CATION POLYMER CAPABLE OF REMOVING POSITIVE CHARGES THROUGH OXIDATIVE RESPONSE, A PREPARATION METHOD AND APPLICATION | PBRM1, SLC7A1, PHAX | LPL 4318/4885LIPG 4118/4885F11 3355/4885 |
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | CNR1, GPR3, CCKAR | LPL 4442/4885LIPG 4726/4885F11 1338/4885 |
| US-20230346953-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | EZH2, BAZ2A, BAZ2B | LPL 2238/4885LIPG 2824/4885F11 3879/4885 |
| US-12491252-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | EZH2, BAZ2A, BAZ2B | LPL 2238/4885LIPG 2824/4885F11 3879/4885 |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | GRM1, GRM2, GRM3 | LPL 3720/4885LIPG 3150/4885F11 3034/4885 |
| US-20240335546-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | EZH2, BAZ2A, BAZ2B | LPL 2238/4885LIPG 2824/4885F11 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.